Cordis CrossFlex LC Stent Boasts 3.2% 30-Day Adverse Event Rate
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Cordis business is highlighting the CrossFlex LC coronary stent's low 3.2%, 30-day major adverse event rate as "among the best reported" following FDA approval of the device Sept. 14. Priced at $1,550-2,150 depending on size, the CrossFlex began shipments in the U.S. immediately following approval, the firm says.
You may also be interested in...
Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales
A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.